Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

1.82
-0.0250-1.36%
Volume:361.23K
Turnover:667.91K
Market Cap:53.73M
PE:-0.79
High:1.88
Open:1.84
Low:1.80
Close:1.84
52wk High:3.84
52wk Low:1.58
Shares:29.61M
Float Shares:21.83M
Volume Ratio:0.81
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3100
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-97.83%
PB:-2.09
PE(LYR):-0.77

Loading ...

NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG

Dow Jones
·
Feb 19

NRX Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Operating Officer Joseph Michael Casper

Reuters
·
Feb 18

NRX Pharmaceuticals Inc - Files Prospectus for $20 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
Feb 17

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 17

BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data

Reuters
·
Feb 17

NRX Pharmaceuticals Advances NRX-100 Toward FDA Approval for Suicidal Depression

Reuters
·
Feb 17

NRX Pharmaceuticals: Will Use Clinical Trial Data in Hand With Proposed Real World Data From Osmind to Apply for NRX-100 Approval

THOMSON REUTERS
·
Feb 17

NRX Pharmaceuticals Inc - Believes Path for NRX-100 Approval Based on Existing Data

THOMSON REUTERS
·
Feb 17

NRX Pharmaceuticals Inc - FDA Advises No Additional Nonclinical Data Needed for NRX Application

THOMSON REUTERS
·
Feb 17

NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Path to New Drug Application With Real World Data and Broader Proposed Indication for NRX-100 (Ketamine) Following Type C FDA Meeting

THOMSON REUTERS
·
Feb 17

NRX Pharmaceuticals Inc - Co to Seek Broader Indication for NRX-100 for Depression

THOMSON REUTERS
·
Feb 17

NRx Pharmaceuticals Inc. Announces Date for 2025 Annual Meeting of Stockholders

Reuters
·
Feb 14

NRX Pharmaceuticals ernennt Joseph M. Casper zum Chief Operating Officer

Reuters
·
Feb 03

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

GlobeNewswire
·
Jan 16

NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG

Dow Jones
·
Jan 15

NRX Pharmaceuticals Submits Real-World Data to FDA for Accelerated Approval of NRX-100

Reuters
·
Jan 14

NRX Pharmaceuticals (Nasdaq:Nrxp) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to Be Submitted to the FDA in Support of NRX-100 Approval

THOMSON REUTERS
·
Jan 14

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 05

NRX Pharmaceuticals and neurocare Group Launch Nationwide Network for Integrated Mental Health Treatment

Reuters
·
Jan 05

NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jan 02